INT212758

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2007
Last Reported 2010
Negated 1
Speculated 3
Reported most in Body
Documents 40
Total Number 44
Disease Relevance 35.60
Pain Relevance 7.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Hmgb1) extracellular region (Hmgb1) cell morphogenesis (Hmgb1)
nucleolus (Hmgb1) chromosome (Hmgb1) nucleus (Hmgb1)
Anatomy Link Frequency
puncture 2
apoptotic cell 2
skeletal muscle tissue 2
somatic cells 1
urine 1
Hmgb1 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 789 99.46 Very High Very High Very High
Inflammation 1206 99.38 Very High Very High Very High
Bioavailability 7 99.00 Very High Very High Very High
antagonist 66 98.84 Very High Very High Very High
Inflammatory response 531 97.40 Very High Very High Very High
cva 73 97.16 Very High Very High Very High
ischemia 372 96.64 Very High Very High Very High
Arthritis 21 93.76 High High
rheumatoid arthritis 68 93.64 High High
Inflammatory mediators 235 92.76 High High
Disease Link Frequency Relevance Heat
Apoptosis 382 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 6 100.00 Very High Very High Very High
Hemorrhagic Shock 51 99.92 Very High Very High Very High
Infection 356 99.90 Very High Very High Very High
Sepsis 1689 99.68 Very High Very High Very High
Fibrosis 145 99.68 Very High Very High Very High
Hydronephrosis 154 99.48 Very High Very High Very High
INFLAMMATION 2007 99.38 Very High Very High Very High
Necrosis 118 99.32 Very High Very High Very High
Injury 778 99.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Glycyrrhizin binding to HMGB1 effectively inhibits its chemoattractant properties [63].
HMGB1 Binding (binding) of
1) Confidence 0.44 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 1.02 Pain Relevance 0.12
To investigate whether HMGB1, released from dying GL26 tumor cells (Ad-TK + GCV treated), was responsible for TLR2 activation in vitro, we inhibited HMGB1 binding using glycyrrhizin, a known antagonist of HMGB1 [40,63].
HMGB1 Binding (binding) of associated with cancer and antagonist
2) Confidence 0.44 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.89 Pain Relevance 0.05
Interestingly, a recent study indicated that HMGB1
           could interact with phosphatidylserine on the cell surface of apoptotic neutrophils, and
           consequently inhibit phagocytotic elimination of apoptotic neutrophils by macrophages
           (Ref. 93). 
HMGB1 Binding (interact) of in neutrophils associated with apoptosis
3) Confidence 0.43 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 1.10 Pain Relevance 0.30
Intracellular HMGB1 as a DNA-binding protein
HMGB1 Binding (binding) of
4) Confidence 0.43 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.38 Pain Relevance 0.05
The HMG boxes enable HMGB1 to bind chromosomal DNA and fulfil its nuclear
         functions, including determination of nucleosomal structure and stability, and regulation
         of gene expression (Ref. 49).


HMGB1 Binding (bind) of
5) Confidence 0.43 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.27 Pain Relevance 0.04
For instance, extracellular HMGB1 can bind to biologically
           active microbial CpG-DNA, and facilitate its innate recognition by the intracellular
           TLR9 receptor, thereby augmenting CpG-DNA-induced inflammatory responses (Refs 52, 71).


HMGB1 Binding (bind) of associated with inflammatory response
6) Confidence 0.43 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.52 Pain Relevance 0.12
This observation suggested a possibility
       that HMGB1 may interact with other serum components to form large (>100 kDa)
       complexes.
HMGB1 Binding (interact) of
7) Confidence 0.43 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.64 Pain Relevance 0.08
Glycyrrhizin binds to both box domains within HMGB1 [40,63] and thus prevents subsequent HMGB1 signaling; specific polyclonal blocking antibodies to HMGB1 [39,77–80] inactivate HMGB1 by binding to it, and reducing its bioavailability.
HMGB1 Binding (binds) of associated with bioavailability
8) Confidence 0.38 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.75 Pain Relevance 0.05
Nevertheless, our present study suggests a novel mechanism by which EGCG prevents HMGB1-mediated cytokine production–potentially by interfering with HMGB1-induced ligand/receptor clustering.
HMGB1 Binding (interfering) of associated with cytokine
9) Confidence 0.36 Published 2007 Journal PLoS ONE Section Body Doc Link PMC2048740 Disease Relevance 0.18 Pain Relevance 0.19
One alternative approach may be to use synthetic, bent oligonucleotides that have a high affinity for HMGB1, and suppress HMGB1-induced proliferation and migration of smooth muscle cells in vitro [176].
HMGB1 Binding (affinity) of in smooth muscle cells
10) Confidence 0.34 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2913853 Disease Relevance 0.76 Pain Relevance 0.14
HMGB1-depleting immunoglobulins (custom antibody generated by New England Peptides) or rabbit IgG isotype control immunoglobulins (Sigma) were affinity purified (Montage, Millipore), tested for LPS contamination (Lonza), and injected in mice on day 19, 22, and 27 after tumor cell implantation (600 ?
HMGB1 Binding (affinity) of associated with cancer
11) Confidence 0.34 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.26 Pain Relevance 0
Here we show that dying glioma cells released HMGB1, as a result of infection and killing with Ad-TK (+GCV); HMGB1 in turn stimulated TLR2-dependent NF?
HMGB1 Binding (killing) of associated with infection and glioma
12) Confidence 0.34 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 1.01 Pain Relevance 0.04
Glycyrrhizin binds to both box domains within HMGB1 [40,63] and thus prevents subsequent HMGB1 signaling; specific polyclonal blocking antibodies to HMGB1 [39,77–80] inactivate HMGB1 by binding to it, and reducing its bioavailability.
HMGB1 Binding (binding) of associated with bioavailability
13) Confidence 0.34 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2621261 Disease Relevance 0.88 Pain Relevance 0.10
HMGB1 as a novel therapeutic target for experimental sepsis
HMGB1 Binding (target) of associated with sepsis
14) Confidence 0.33 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.49 Pain Relevance 0.04
Indeed, many exogenous bacterial products (such as endotoxin or CpG-DNA) (Refs 52, 71, 72) or endogenous proteins (such as human
       thrombomodulin, IgG1 or IL-1) (Refs 115, 150) may physically interact with HMGB1 to form
       various complexes. 
HMGB1 Binding (interact) of
15) Confidence 0.33 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 0.26 Pain Relevance 0
Will HMGB1 ever become a clinically feasible therapeutic target for human sepsis?
HMGB1 Binding (target) of associated with sepsis
16) Confidence 0.33 Published 2008 Journal Expert Reviews in Molecular Medicine Section Body Doc Link PMC2586610 Disease Relevance 1.36 Pain Relevance 0.47
Following acute inflammation, the immune system is able to recognize the HMGB1 as a hazard molecule.
HMGB1 Binding (recognize) of in immune system associated with inflammation
17) Confidence 0.33 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC2902015 Disease Relevance 2.38 Pain Relevance 0.56
Our results suggest that determination of HMGB1 and MIF reflects the extent of ischemic injury.
HMGB1 Spec (determination) Binding (determination) of associated with injury
18) Confidence 0.33 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC3010695 Disease Relevance 0.87 Pain Relevance 0.16
To determine whether HMGB1 and MIF were released and associated with hepatocellular injury, Western blot analysis was performed on effluent samples obtained at defined time points during the ischemia period.
HMGB1 Binding (associated) of associated with ischemia and injury
19) Confidence 0.33 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC3010695 Disease Relevance 0.89 Pain Relevance 0.27
Vascular endothelial cells were negative for HMGB1 at all time points.
HMGB1 Binding (negative) of in endothelial cells
20) Confidence 0.33 Published 2010 Journal Mediators of Inflammation Section Body Doc Link PMC3010695 Disease Relevance 0.87 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox